EP1168923A4 - Dna vaccination for treatment of autoimmune disease - Google Patents

Dna vaccination for treatment of autoimmune disease

Info

Publication number
EP1168923A4
EP1168923A4 EP00912207A EP00912207A EP1168923A4 EP 1168923 A4 EP1168923 A4 EP 1168923A4 EP 00912207 A EP00912207 A EP 00912207A EP 00912207 A EP00912207 A EP 00912207A EP 1168923 A4 EP1168923 A4 EP 1168923A4
Authority
EP
European Patent Office
Prior art keywords
autoimmune disease
treatment
dna vaccination
vaccination
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00912207A
Other languages
German (de)
French (fr)
Other versions
EP1168923B1 (en
EP1168923A1 (en
Inventor
Lawrence Steinman
Pedro Jose Ruiz
Hideki Garren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to DK05015105.9T priority Critical patent/DK1621208T3/en
Priority to EP09014922A priority patent/EP2177228A1/en
Priority to EP05015105A priority patent/EP1621208B1/en
Publication of EP1168923A1 publication Critical patent/EP1168923A1/en
Publication of EP1168923A4 publication Critical patent/EP1168923A4/en
Application granted granted Critical
Publication of EP1168923B1 publication Critical patent/EP1168923B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treated by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-³ and IL-15, are reduced.
EP00912207A 1999-03-12 2000-03-10 Dna vaccination for treatment of autoimmune disease Expired - Lifetime EP1168923B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DK05015105.9T DK1621208T3 (en) 1999-03-12 2000-03-10 DNA vaccination to treat sutoimmune disease
EP09014922A EP2177228A1 (en) 1999-03-12 2000-03-10 DNA vaccination for treatment of autoimmune disease
EP05015105A EP1621208B1 (en) 1999-03-12 2000-03-10 DNA vaccination for treatment of autoimmune disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26759099A 1999-03-12 1999-03-12
US267590 1999-03-12
PCT/US2000/006233 WO2000053019A1 (en) 1999-03-12 2000-03-10 Dna vaccination for treatment of autoimmune disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05015105A Division EP1621208B1 (en) 1999-03-12 2000-03-10 DNA vaccination for treatment of autoimmune disease

Publications (3)

Publication Number Publication Date
EP1168923A1 EP1168923A1 (en) 2002-01-09
EP1168923A4 true EP1168923A4 (en) 2002-06-26
EP1168923B1 EP1168923B1 (en) 2005-11-02

Family

ID=23019424

Family Applications (3)

Application Number Title Priority Date Filing Date
EP09014922A Withdrawn EP2177228A1 (en) 1999-03-12 2000-03-10 DNA vaccination for treatment of autoimmune disease
EP05015105A Expired - Lifetime EP1621208B1 (en) 1999-03-12 2000-03-10 DNA vaccination for treatment of autoimmune disease
EP00912207A Expired - Lifetime EP1168923B1 (en) 1999-03-12 2000-03-10 Dna vaccination for treatment of autoimmune disease

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP09014922A Withdrawn EP2177228A1 (en) 1999-03-12 2000-03-10 DNA vaccination for treatment of autoimmune disease
EP05015105A Expired - Lifetime EP1621208B1 (en) 1999-03-12 2000-03-10 DNA vaccination for treatment of autoimmune disease

Country Status (9)

Country Link
EP (3) EP2177228A1 (en)
JP (1) JP2003508346A (en)
AT (2) ATE453404T1 (en)
CA (1) CA2363269C (en)
DE (2) DE60043624D1 (en)
DK (2) DK1168923T3 (en)
ES (2) ES2251974T3 (en)
PT (1) PT1621208E (en)
WO (1) WO2000053019A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544669B2 (en) * 2001-11-21 2009-06-09 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
AU2007326171B2 (en) 2006-11-30 2012-11-15 Medipost Co., Ltd. Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
CN100571786C (en) * 2007-03-26 2009-12-23 中国农业大学 A kind of vaccine that prevents and/or treats autoimmune disease
KR20100054711A (en) * 2008-11-14 2010-05-25 메디포스트(주) Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases
SE535625C2 (en) 2010-10-28 2012-10-16 Toleranzia Ab New compositions and procedures for the treatment of autoimmune and allergic diseases
ES2658154T3 (en) 2011-02-02 2018-03-08 Medipost Co., Ltd. Use of ICAM-1 for the prevention or treatment of neurological diseases
GB201112806D0 (en) * 2011-07-26 2011-09-07 Bauer Johann Use of epitopes inducing specific tolerance for the prevention of tissue rejection
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10898590B2 (en) 2015-09-21 2021-01-26 Kolon Life Science, Inc. Method for delivery of biological molecule to nervous tissue
KR20170034701A (en) * 2015-09-21 2017-03-29 코오롱생명과학 주식회사 Composition for treating pain
WO2023086969A2 (en) * 2021-11-12 2023-05-19 Ichor Medical Systems Inc. Treatment methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045144A1 (en) * 1996-05-29 1997-12-04 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
WO1997046253A2 (en) * 1996-06-03 1997-12-11 Powderject Vaccines, Inc. Immunotherapy for autoimmune disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045144A1 (en) * 1996-05-29 1997-12-04 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
WO1997046253A2 (en) * 1996-06-03 1997-12-11 Powderject Vaccines, Inc. Immunotherapy for autoimmune disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOW YH ET AL: "Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes", JOURNAL OF IMMUNOLOGY, vol. 160, no. 3, 1 February 1998 (1998-02-01), pages 1320 - 1329, XP002196042 *
GARREN HIDEKI ET AL: "Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway.", IMMUNITY, vol. 15, no. 1, July 2001 (2001-07-01), pages 15 - 22, XP002196044, ISSN: 1074-7613 *
NOWICKA J ET AL: "Protective effect of naked DNA immunization in experimental autoimmune encephalitis.", JOURNAL OF NEUROIMMUNOLOGY, vol. 90, no. 1, 1 September 1998 (1998-09-01), pages 102 abstract 582, XP001068792, ISSN: 0165-5728 *
RUIZ PJ ET AL: "Suppressive Immunization with DNA Encoding a Self-Peptide Prevents Autoimmune Disease: Modulation of T Cell Costimulation", JOURNAL OF IMMUNOLOGY, vol. 162, no. 6, 15 March 1999 (1999-03-15), pages 3336 - 3341, XP002196043 *

Also Published As

Publication number Publication date
ES2338890T3 (en) 2010-05-13
EP1621208A1 (en) 2006-02-01
DK1621208T3 (en) 2010-05-10
DE60023673T2 (en) 2006-07-20
ATE453404T1 (en) 2010-01-15
ES2251974T3 (en) 2006-05-16
EP1168923B1 (en) 2005-11-02
WO2000053019A1 (en) 2000-09-14
EP2177228A1 (en) 2010-04-21
JP2003508346A (en) 2003-03-04
ATE308244T1 (en) 2005-11-15
EP1168923A1 (en) 2002-01-09
EP1621208B1 (en) 2009-12-30
DE60023673D1 (en) 2005-12-08
CA2363269C (en) 2012-06-12
CA2363269A1 (en) 2000-09-14
PT1621208E (en) 2010-04-07
DE60043624D1 (en) 2010-02-11
DK1168923T3 (en) 2006-03-20

Similar Documents

Publication Publication Date Title
EP1168923A4 (en) Dna vaccination for treatment of autoimmune disease
DE69737969D1 (en) DNA VACCINATION TO INTRODUCE A SUPPRESSIVE T CELL RESPONSE
IL92382A0 (en) Immunotherapy involving cd28 stimulation
GB2217718B (en) Recombinant viruses,vaccines containing them and in vitro cell cultures thereof
DK0633929T3 (en) Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
EP0253887A1 (en) Low dosage of interferon to enhance vaccine efficiency.
SG170001A1 (en) Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
IL148008A0 (en) Conditional immortalisation of cells
IL163701A0 (en) Modified vaccinia virus ankara for the vaccinationof neonates
EP0249629A4 (en) Methods and materials for alleviation of pain symptoms of malignant neoplasia.
PT1699480E (en) Allogeneic tumor therapeutic agent
ATE226087T1 (en) USE OF NOVEL CELL DEATH INDUCING AGENTS IN SYNERGISM WITH INTERFERON
CN204582025U (en) A kind of public place sterilamp
WO2002043651A3 (en) Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
PH23658A (en) Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
CN201930149U (en) Multifunctional wheelchair
Kedar et al. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
CN211722488U (en) Massage chair capable of being placed outdoors for use
HU0000185D0 (en) Plasmids, their construction and their use in the manufacture of interleurin-4 and interleukin-4 muteins
AU1592801A (en) Methods of treating inflammatory bowel disease using cholera toxin B subunit
LLOYD CELL TO CELL TRANSFER OF INTERFERON-INDUCED ANTIPROLIFERATIVE ACTIVITY IN VITRO AND ANTIVIRAL ACTIVITY IN VIVO.
DK1100515T3 (en) Ex vivo treatment of allogeneic and xenogenic T cells with pg39 antagonists
David Review of Psychologische Grundlagenforschung: Ethik und Recht.
范萍 et al. Effects of HHV-6 Infection in Vitro on Cytokines Induction and NK Activity of Peripherial Blood Mononuclear Cells
CN111109235A (en) Portable mosquito-repellent aromatherapy device without external power supply

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 01N 63/00 A, 7A 01N 65/00 B, 7A 61K 31/70 B, 7A 61K 39/00 B, 7A 61K 39/38 B, 7C 12N 15/00 B, 7C 12N 15/08 B, 7C 12N 15/09 B, 7C 12N 15/63 B, 7C 12N 15/70 B, 7C 07K 14/47 B, 7A 61P 37/06 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020515

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030122

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 60023673

Country of ref document: DE

Date of ref document: 20051208

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060202

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20060220

Year of fee payment: 7

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2251974

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051102

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20110316

Year of fee payment: 12

Ref country code: IE

Payment date: 20110328

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20110315

Year of fee payment: 12

Ref country code: PT

Payment date: 20110316

Year of fee payment: 12

Ref country code: CH

Payment date: 20110315

Year of fee payment: 12

Ref country code: AT

Payment date: 20110315

Year of fee payment: 12

Ref country code: NL

Payment date: 20110323

Year of fee payment: 12

Ref country code: LU

Payment date: 20110317

Year of fee payment: 12

Ref country code: FI

Payment date: 20110315

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20110315

Year of fee payment: 12

Ref country code: ES

Payment date: 20110315

Year of fee payment: 12

Ref country code: GB

Payment date: 20110309

Year of fee payment: 12

Ref country code: FR

Payment date: 20110414

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20110329

Year of fee payment: 12

Ref country code: DE

Payment date: 20110517

Year of fee payment: 12

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20120910

BERE Be: lapsed

Owner name: THE *BOARD OF TRUSTEES OF THE LELAND STANFORD JUNI

Effective date: 20120331

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20121001

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120310

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120311

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120910

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 308244

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120310

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20121130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60023673

Country of ref document: DE

Effective date: 20121002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120331

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120402

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120310

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120331

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120310

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120331

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20131030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120311

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121002